Tony Hitchcock | 10/17/2013
Over recent weeks I have been intrigued to hear some highly negative comments from people outside of the biopharm community on the industries economic value and also concerns regarding the public perception of the potential use of live recombinant products being a reason not to progress along this track. Over the last 30 years, the industry has grown from what was in many cases nothing more than a scientific novelty, into multi-billion dollar products. This has been achieved in the face...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma AI Commercial Excellence & Health 2025
September 01 - 03, 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More
AI for Pharma & Healthcare
23 - 25 September, 2025
Amsterdam
Register Now |
View Agenda |
Learn More